Bioventus Reports Second Quarter Financial Results

Q2 Revenue Advanced by 10.3%, Organic Growth* by 13.9% Q2 Gross Margin Expanded 350 bps and Adjusted Gross Margin* 180 bps Cash from Operations of $15.2 million Increased 40.5% Raising Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic Priorities DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and si ...